ACCESS PHARMACEUTICALS, INC.
(OTC Bulletin Board: ACCP) announced today that it has continued to expand
the number of clinical trial sites for its on-going Phase 2 trial of
ProLindac in patients with recurrent platinum-sensitive ovarian cancer. The
number of sites opened has now reached 11, up from two initial sites when
the trial was commenced last year. The additional sites allow for the
potential of more rapid patient accrual.
"We are pleased with the increase in hospitals that are interested in
participating in our ProLindac ovarian cancer trial," said Stephen R.
Seiler, Access' Chief Executive Officer. "The expanded number of sites also
gives us the advantage of being able to draw from a larger potential
patient population for trial enrolment."
ProLindac, is a novel DACH platinum prodrug which has been shown to be
active in a wide variety of solid tumors in both preclinical models and in
human trials. Access believes ProLindac's unique molecular design
potentially could eliminate some of the toxic neurological side effects
seen in the currently marketed DACH platinum, oxaliplatin, which has sales
in excess of $2 billion. In a Phase 1 clinical study, at least five times
more DACH platinum could be administered to patients with ProLindac(TM)
than oxaliplatin before the onset of toxicity.
About Access
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company
that develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include ProLindac(TM),
currently in Phase II clinical testing of patients with ovarian cancer and
MuGard(TM) for the management of patients with mucositis. The Company also
has other advanced drug delivery technologies including
Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For
additional information on Access Pharmaceuticals, please visit our website
at accesspharma.
This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as
amended, and that involve risks and uncertainties, including statements
relating to the value of our products in the market, our ability to achieve
clinical and commercial success, our ability to expand our clinical trial
sites and enroll additional patients and our ability to successfully
develop marketed products. These statements are subject to numerous risks,
including but not limited to the risks detailed in the Company's Annual
Report on Form 10-KSB for the year ended December 31, 2006 and other
reports filed by us with the Securities and Exchange Commission.
Access Pharmaceuticals, Inc.
accesspharma